SCHEDULE: NEA Affiliates Boost X4 Pharma Stake to 9.99%

Growth Equity Opportunities 18 VGE, an affiliate of New Enterprise Associates, increased its beneficial ownership in X4 Pharmaceuticals, Inc. to 9.99% through a recent private placement.

Summary

• Growth Equity Opportunities 18 VGE, LLC (GEO), an affiliate of New Enterprise Associates (NEA), has increased its beneficial ownership in X4 Pharmaceuticals, Inc.
• The increase stems from GEO's participation in a private placement that closed on August 13, 2025.
• GEO purchased 1,734,184 shares of Common Stock at $1.42 per share.
• GEO also acquired Pre-Funded Warrants to purchase 5,311,810 shares of Common Stock at $1.419 per warrant, with an exercise price of $0.001 per share.
• The total deemed beneficial ownership for GEO and its affiliated reporting persons is now 2,243,658 shares of X4 Pharmaceuticals Common Stock.
• This represents 9.99% of the Issuer's outstanding Common Stock, calculated based on 22,459,047 shares outstanding after the private placement.
• The funds for this acquisition came from GEO's working capital.
• A Registration Rights Agreement was also entered into, providing certain registration rights for the acquired securities.

Sentiment

Score: 7

Explanation: The filing reflects a significant investment by a reputable venture capital firm, indicating confidence in the issuer. While it's an ownership update rather than a performance report, the capital infusion from the private placement is generally positive for the company's financial stability and future operations.

Positives

• Significant investment by a major venture capital firm (NEA affiliates) indicates confidence in X4 Pharmaceuticals' future prospects.
• The private placement provides X4 Pharmaceuticals with additional capital.
• The acquisition is for investment purposes, suggesting a long-term strategic interest rather than an immediate activist agenda.

Risks

• The Pre-Funded Warrants include a limitation on exercise if it results in beneficial ownership exceeding 4.99%, which can be increased or decreased upon 61 days' prior notice, not to exceed 19.99%. This could impact the immediate liquidity or control potential of the warrant holder.

Future Outlook

The reporting persons acquired the shares for investment purposes and currently have no present plans for extraordinary corporate transactions, asset sales, changes to management or the board, capitalization or dividend policy changes, business or corporate structure changes, or actions to impede acquisition of control, delist securities, or terminate registration.

Industry Context

This filing indicates continued investment interest in the biotechnology and pharmaceutical sector, specifically in companies like X4 Pharmaceuticals. The participation of a prominent venture capital firm like NEA suggests a belief in the long-term potential of X4 Pharmaceuticals' pipeline or strategic direction, aligning with broader trends of private capital supporting innovative life sciences companies.

Stakeholder Impact

• Shareholders: The private placement dilutes existing shareholders but also provides capital for the company's operations, potentially supporting future growth and value creation.
• Creditors: The capital raise could improve the company's financial position, potentially reducing credit risk.

Next Steps

• The acquired securities are subject to a Registration Rights Agreement, implying future potential registration for resale.

Key Dates

Recommendation

The filing indicates a significant investment by a major venture capital firm, which is a positive signal of confidence in X4 Pharmaceuticals. However, as a Schedule 13D, it primarily details an ownership stake rather than providing new operational or financial performance data. The private placement itself, while providing capital, also involves dilution. Without further information on the company's recent performance, pipeline progress, or strategic initiatives, a 'hold' recommendation is prudent, acknowledging the positive investor interest while awaiting more comprehensive operational updates.

Keywords

X4 Pharmaceuticals, XFOR, Schedule 13D, SEC Filing, Beneficial Ownership, Private Placement, Growth Equity Opportunities 18 VGE, NEA, Venture Capital, Biotechnology, Pharmaceuticals, Investment, Common Stock, Pre-Funded Warrants